{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"groups":[{"description":"Participants with neuroblastoma.","id":"OG000","title":"Cohort 3"}],"populationDescription":"Included safety-evaluable population, defined as patients who received any amount of study drug.","reportingStatus":"POSTED","timeFrame":"Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months)","title":"DOR as Determined by the Investigator Using mINRC in Participants With Neuroblastoma","type":"SECONDARY"}